摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Isopropyl-amino-2-methyl-butanon-(3) | 90226-43-0

中文名称
——
中文别名
——
英文名称
2-Isopropyl-amino-2-methyl-butanon-(3)
英文别名
3-Isopropylamino-3-methyl-butan-2-on;2-Butanone, 3-(isopropylamino)-3-methyl-;3-methyl-3-(propan-2-ylamino)butan-2-one
2-Isopropyl-amino-2-methyl-butanon-(3)化学式
CAS
90226-43-0
化学式
C8H17NO
mdl
MFCD18813333
分子量
143.229
InChiKey
BGNFOZIPTOOXGD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    10
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.875
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
    申请人:ALIOS BIOPHARMA, INC.
    公开号:US20140179627A1
    公开(公告)日:2014-06-26
    Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    本文披露了核苷酸类似物,合成核苷酸类似物的方法,以及利用一个或多个核苷酸类似物治疗HCV感染等疾病和/或症状的方法。
  • INHIBITORS OF POLO-LIKE KINASE
    申请人:Galemmo Robert A.
    公开号:US20110212942A1
    公开(公告)日:2011-09-01
    The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, X, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
    本发明提供了具有以下式子(I)结构的化合物,或其盐或溶剂化物,其中环A,X,R1,R2,R3,R4,R5和R6在此被定义。本发明还提供了包括本发明化合物的制药组合物以及使用本发明化合物和组合物的方法,例如在治疗和预防各种疾病,如帕金森病中的应用。
  • NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND
    申请人:Mitsubishi Tanabe Pharma Corporation
    公开号:EP3683222B1
    公开(公告)日:2021-10-06
  • Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
    申请人:Novo Nordisk A/S
    公开号:US20200223889A1
    公开(公告)日:2020-07-16
    The present invention relates to novel peptide compounds which are effective as melanocortin 4 receptor agonists, to the use of the compounds in medicine, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds for the manufacture of 5 medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity or overweight as well as a variety of diseases or conditions associated with obesity.
  • US8445503B2
    申请人:——
    公开号:US8445503B2
    公开(公告)日:2013-05-21
查看更多